History

BioNTech US was created from BioNTech SE’s purchase of Neon Therapeutics, a U.S. biotechnology company working on neoantigen-based cancer immunotherapies and T-cell treatments. BioNTech announced the proposed transaction in January 2020, shortly after its 2019 public listing, and completed the merger on May 6, 2020. The acquired company became BioNTech US Inc., a wholly owned subsidiary based in Cambridge, Massachusetts, and served as BioNTech’s U.S. headquarters. The acquisition expanded BioNTech’s presence in the American biotechnology ecosystem and complemented its existing research in individualized cancer vaccines. Neon’s approach centered on identifying tumor-specific mutations and developing therapies intended to stimulate T-cell responses against those targets. Within BioNTech’s group structure, the Cambridge operation became a platform for U.S. research, clinical development, business development, and interaction with American institutions and regulators. The subsidiary’s visibility increased sharply during the COVID-19 pandemic. BioNTech partnered with Pfizer to develop an mRNA vaccine, later marketed as Comirnaty. The vaccine received U.S. emergency authorization in December 2020 and subsequently obtained full FDA approval for specified uses. Pfizer played a central role in late-stage clinical execution, regulatory interaction, manufacturing coordination, supply, and commercialization in the United States, while BioNTech contributed the mRNA vaccine technology and remained a principal development partner. BioNTech US formed part of the American-facing infrastructure supporting this global collaboration. Public communication around the vaccine included education and confidence-building initiatives rather than only conventional product advertising. In 2021, Pfizer, BioNTech, and health organizations supported the Because Of This campaign, which used real personal moments to connect vaccination with the restoration of social life. Related communications emphasized learning about vaccination and rebuilding confidence amid widespread misinformation and uncertainty. These efforts illustrate the unusual public-health and commercial environment in which the BioNTech brand became known in the United States. After the pandemic emergency, BioNTech’s strategic emphasis increasingly returned to oncology while retaining infectious-disease programs. The broader group has pursued individualized cancer vaccines, off-the-shelf immunotherapies, antibody-based medicines, cell therapies, and additional mRNA vaccine candidates. BioNTech US remains part of that international development system, but available sources do not establish a separate product portfolio or independent financial reporting for the U.S. subsidiary. The company is consequently best characterized as a U.S. headquarters and operating subsidiary whose work is integrated with BioNTech SE’s global research and business activities.

2024
BioNTech agrees to acquire Biotheus
[3]BioNTech announcement on the Biotheus acquisitionsec.gov
The parent company announced an agreement to acquire Biotheus and obtain global rights to the investigational bispecific antibody BNT327/PM8002 as part of its oncology strategy.
2021
Comirnaty receives full FDA approval
[5]Pfizer and BioNTech Comirnaty marketing discussionprweek.com
The FDA granted full approval to Comirnaty for specified uses, enabling the partners to move from emergency-use communications toward a broader branded-information and advertising phase.
2020
Neon Therapeutics acquisition closes
[2]BioNTech SEC registration statement covering the Neon Therapeutics acquisitionsec.gov
BioNTech completed its acquisition of Neon Therapeutics. The acquired company became BioNTech US Inc., operated as a wholly owned subsidiary, and provided the group with a Cambridge, Massachusetts headquarters and U.S. oncology capabilities.
2020
U.S. emergency authorization of the Pfizer-BioNTech vaccine
[6]U.S. emergency authorization of the Pfizer-BioNTech vaccinebiontech.com
The Pfizer-BioNTech COVID-19 vaccine received U.S. emergency authorization, making the collaboration one of the most prominent applications of mRNA technology in public health.

Products and positioning

A U.S.-based biotechnology operating platform focused on mRNA medicine, cancer immunotherapy, infectious-disease vaccines, and strategic partnerships within the BioNTech group.

mRNA vaccine · 2020
Comirnaty
Comirnaty is the Pfizer-BioNTech COVID-19 vaccine collaboration and the best-known product associated with BioNTech in the United States. It uses messenger RNA to instruct cells to produce an antigen that stimulates an immune response. Pfizer led major U.S. commercialization and distribution activities, while BioNTech supplied the underlying biotechnology partnership and remained a principal developer. The vaccine moved from emergency authorization in 2020 to full FDA approval for specified uses in 2021.
Oncology platform
Individualized cancer immunotherapies
BioNTech’s individualized oncology programs are designed to use information from a patient’s tumor to create treatments directed at tumor-specific targets. The work grew out of the company’s personalized cancer-vaccine strategy and was complemented by the Neon acquisition, which added U.S. expertise in neoantigen and T-cell approaches. These programs are investigational and should not be treated as approved products of BioNTech US.
Bispecific antibody · 2024
BNT327/PM8002
BNT327/PM8002 is an investigational bispecific antibody targeting PD-L1 and VEGF-A. BioNTech obtained global rights through its planned acquisition of Biotheus, with the asset positioned for development in oncology and potential combination therapies. It is a group-level pipeline asset rather than a separately commercialized BioNTech US product.

Controversies

2021
BioNTech vaccine batch paused in Hong Kong and Macau after vial-cap defect
BioNTech notified Fosun Pharma of a vial-cap defect in BNT162b2 batch 210102 supplied to Hong Kong and Macau. BioNTech and Fosun Pharma began investigating the cause, and the batch was paused for vaccination until the investigation ends; Fosun Pharma also said batch 210104 intended for Hong Kong would be stored and not sent to vaccination sites pending further notice.
Source

Marketing campaigns

2021Because Of This
United States
Pfizer, BioNTech, and health organizations supported a vaccine-confidence campaign built around real personal moments such as reunions, family contact, and shared experiences. The campaign sought to counter uncertainty and misinformation by linking vaccination with the possibility of returning to ordinary social life.
Outcome. The campaign ran through television, social media, and donated out-of-home media, directing audiences toward additional vaccine information.
Source
2021It's Up To You
United States
The vaccine communication environment around Comirnaty incorporated an empathetic public-information approach that encouraged people to become informed rather than relying only on a direct product-sales message. The approach was associated with broader vaccine education efforts and the partners’ transition toward communication after regulatory approval.
Outcome. The campaign framework was intended to increase confidence in vaccination and reach audiences with different reasons for hesitancy.
Source

Brand decisions

2024
Acquire Biotheus for oncology expansionM&A
Background
BioNTech pursued additional oncology capabilities and global rights to an investigational bispecific antibody for potential combination treatments.
Action taken
BioNTech agreed to acquire all issued share capital of Biotheus and obtain rights to BNT327/PM8002.
Aftermath
The deal was positioned as part of the parent company’s oncology strategy; the available material does not establish a separate operational consequence for BioNTech US.
Upfront consideration. $800 million (Announced in 2024; transaction terms also included up to $150 million in potential milestone payments)
Source
2020
Acquire Neon Therapeutics and establish BioNTech USM&A
Background
BioNTech sought to strengthen its individualized cancer-immunotherapy and T-cell capabilities and establish a larger U.S. operating presence.
Action taken
The company completed an all-stock acquisition of Neon Therapeutics, which became BioNTech US Inc., a wholly owned subsidiary based in Cambridge, Massachusetts.
Aftermath
The transaction added neoantigen-based T-cell expertise and made the acquired Cambridge organization BioNTech’s U.S. headquarters.
Source

Recent events

2022.02.16
Reported2022.02.16
BioNTech introduces BioNTainer manufacturing solution[8]BioNTech推出BioNTainer制造方案finance.yahoo.com
BioNTech introduced its BioNTainer container-based approach for establishing scalable mRNA vaccine manufacturing facilities in Africa. Construction of the first facility was planned to start in mid-2022.
2021.08.23
Reported2026.11.01
FDA fully approves Pfizer/BioNTech COVID-19 vaccine[9]FDA 全面批准 Pfizer/BioNTech 新冠疫苗wbrz.com
The FDA fully approved Pfizer/BioNTech's COVID-19 vaccine on August 23, 2021; the vaccine will be marketed as Comirnaty for prevention of COVID-19 in individuals aged 16 and older.
2021.07.21
Reported2021.07.21
Pfizer and BioNTech sign vaccine manufacturing letter of intent with Biovac[10]辉瑞和BioNTech与Biovac签署疫苗生产意向书stripes.com
Pfizer and BioNTech signed a letter of intent with Biovac Institute to manufacture their COVID-19 vaccine at Biovac's Cape Town facility. The companies said the facility was expected to join their supply chain by the end of 2021, with finished-dose production planned to begin in 2022.
2021.05.10
Reported2021.05.10
BioNTech announces planned Southeast Asia expansion[11]BioNTech 宣布计划拓展东南亚业务finanznachrichten.de
BioNTech announced plans to expand its global footprint to Asia by establishing its first regional headquarters for Southeast Asia in Singapore, including an mRNA manufacturing facility.
2021.03.24
BioNTech vaccine batch paused in Hong Kong and Macau after vial-cap defect[7]BioNTech vaccine batch paused in Hong Kong and Macau after vial-cap defectnbd.com.cn
BioNTech notified Fosun Pharma of a vial-cap defect in BNT162b2 batch 210102 supplied to Hong Kong and Macau. BioNTech and Fosun Pharma began investigating the cause, and the batch was paused for vaccination until the investigation ends; Fosun Pharma also said batch 210104 intended for Hong Kong would be stored and not sent to vaccination sites pending further notice.
2021.03.02
Reported2021.03.02
Evonik expands strategic partnership with BioNTech for vaccine lipids[12]赢创扩大与BioNTech的疫苗脂质战略合作news-medical.net
Evonik and BioNTech expanded their strategic partnership to produce specialty lipids for COVID-19 vaccines at Evonik sites in Germany, with commercial quantities planned as early as the second half of 2021.
2021.02.19
Reported2021.02.22
Pfizer announces expanded COVID-19 vaccine production capacity[13]Pfizer宣布扩大新冠疫苗产能medicaldialogues.in
Pfizer CEO Albert Bourla said the company would use additional manufacturing capacity and work with new suppliers to increase production of its COVID-19 vaccine. The announced plans include additional capacity at its Kalamazoo, Groton and McPherson sites.
2021.02.01
Reported2021.02.01
BioNTech and Pfizer announce increased EU vaccine deliveries[14]BioNTech与Pfizer宣布增加对欧盟的疫苗交付dw.com
BioNTech and Pfizer announced that they would increase coronavirus vaccine deliveries to the European Union, pledging up to 75 million additional doses in the spring. They said increased production capabilities would allow them to accelerate supplies.
2020.11.25
QIAGEN and BioNTech announce companion diagnostic collaboration[15]QIAGEN与BioNTech宣布伴随诊断合作selectscience.net
QIAGEN announced a strategic collaboration with BioNTech to develop and commercialize a tissue-based companion diagnostic for use with investigational cancer treatment BNT113.
2020.07.31
Reported2020.07.31
BioNTech and Regeneron announce melanoma trial collaboration[16]BioNTech与Regeneron宣布黑色素瘤临床试验合作finance.yahoo.com
BioNTech announced a strategic collaboration with Regeneron for a clinical trial combining BioNTech's BNT111 FixVac candidate and Regeneron's Libtayo for melanoma. The companies said they planned to jointly conduct a randomized Phase 2 study and share the trial's development costs equally.

Biontech